Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. by Lawrie, C, Chi, J, Taylor, S, Tramonti, D, Ballabio, E, Palazzo, S, Saunders, N, Pezzella, F, Boultwood, J, Wainscoat, J, Hatton, C

“…However, the role of microRNAs in lymphoma is poorly understood. Therefore, we undertook a comprehensive study of microRNA expression in two of the most common lymphomas: diffuse large B-cell lymphoma (DLBCL) (n = 80) and follicular lymphoma (FCL) (n = 18) using microarrays containing probes for 464 human microRNAs. …”

Immunochemical studies of antigenic lymphoma-associated proteins. by Pulford, K, Roberton, H, Banham, A, Hatton, C, Mason, D

“…We have previously reported that plasma from patients with anaplastic lymphoma kinase (ALK)-positive lymphoma contains antibodies against the oncogenic kinase NPM-ALK protein characteristic of this disease. …”

INVESTIGATION OF THE MOLECULAR BASIS OF LENALIDOMIDE TREATMENT IN LYMPHOMA CELL LINES by Ballabio, E, Fernandez-Santamaria, C, Tramonti, D, Chen, X, Wainscoat, J, Boultwood, J, Hatton, C, Lawrie, C

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. by Cooper, C, Lawrie, C, Liggins, A, Collins, G, Hatton, C, Pulford, K, Banham, A

“…Peripheral T-cell lymphomas (PTCL) are generally less common and pursue a more aggressive clinical course than B-cell lymphomas, with the T-cell phenotype itself being a poor prognostic factor in adult non-Hodgkin lymphoma (NHL). …”

Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma. by Passalidou, E, Stewart, M, Trivella, M, Steers, G, Pillai, G, Dogan, A, Leigh, I, Hatton, C, Harris, A, Gatter, K, Pezzella, F

“…The few studies published on angiogenesis in lymphoma have raised the question of whether or not microvessel density (MVD) is associated with more aggressive disease and have reported the observation that in follicular lymphomas, vessels are mature rather than immature. …”

Serologic detection of diffuse large B-cell lymphoma-associated antigens. by Liggins, A, Guinn, B, Hatton, C, Pulford, K, Banham, A

“…Diffuse large B-cell lymphoma (DLBCL) accounts for 30-40% of all adult non-Hodgkin's lymphomas, yet the understanding of its underlying genetic abnormalities remains poor. …”

Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. by Lawrie, C, Marafioti, T, Hatton, C, Dirnhofer, S, Roncador, G, Went, P, Tzankov, A, Pileri, SA, Pulford, K, Banham, A

“…We used carbohydrate array technology to compare serum antibody (IgG and IgM) levels against 37 different carbohydrates between classical Hodgkin's lymphoma (cHL) patients and age/sex-matched healthy controls. …”

Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas. by Patel, S, Murphy, D, Haralambieva, E, Abdulla, Z, Wong, K, Chen, H, Gould, E, Roncador, G, Hatton, C, Anderson, A, Banham, A, Pulford, K

“…Our identification of FADD as a lymphoma-associated autoantigen in T-cell lymphoma patients raises the possibility that pFADD, with its correlation with cell cycle, may possess role(s) in human T-cell lymphoma development. …”

Primary cutaneous large cell CD30+ lymphoma in a renal transplant recipient. by Cooper, S, Turner, G, Hollowood, K, Gatter, K, Hatton, C, Gray, D, Russell-Jones, R, Wojnarowska, F

RNASET2 - An autoantigen in anaplastic large cell lymphoma identified by protein array analysis by Patel, S, Chen, H, Monti, L, Gould, E, Haralambieva, E, Schmid, J, Toomey, D, Woessmann, W, Roncador, G, Hatton, C, Liggins, A, Taramelli, R, Banham, A, Acquati, F, Murphy, D, Pulford, K

“…Preliminary screening of a protein macroarray, containing more than 12,000 different proteins, with sera from anaplastic lymphoma kinase (ALK)-negative and ALK-positive anaplastic large cell lymphoma (ALCL) patients identified ribonuclease and tumour suppressor protein Ribonuclease T2 (RNASET2), phosphatase lipid phosphate phosphatase-related protein type 3 (LPPR3) and apoptotic adaptor molecule Fas-associating protein (FADD) as ALK-negative ALCL-associated TAAs. …”

RNASET2--an autoantigen in anaplastic large cell lymphoma identified by protein array analysis. by Patel, S, Chen, H, Monti, L, Gould, E, Haralambieva, E, Schmid, J, Toomey, D, Woessmann, W, Roncador, G, Hatton, C, Liggins, A, Taramelli, R, Banham, A, Acquati, F, Murphy, D, Pulford, K

“…Preliminary screening of a protein macroarray, containing more than 12,000 different proteins, with sera from anaplastic lymphoma kinase (ALK)-negative and ALK-positive anaplastic large cell lymphoma (ALCL) patients identified ribonuclease and tumour suppressor protein Ribonuclease T2 (RNASET2), phosphatase lipid phosphate phosphatase-related protein type 3 (LPPR3) and apoptotic adaptor molecule Fas-associating protein (FADD) as ALK-negative ALCL-associated TAAs. …”

Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. by Pulford, K, Falini, B, Banham, A, Codrington, D, Roberton, H, Hatton, C, Mason, D

“…Oncogenic anaplastic lymphoma kinase (ALK) fusion proteins (nucleophosmin-ALK [NPM-ALK] and other variants) are expressed in many cases of anaplastic large-cell lymphoma (ALCL) but are absent from normal tissues. …”

Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma by Ait-Tahar, K, Liggins, A, Collins, G, Campbell, A, Barnardo, M, Lawrie, C, Moir, D, Hatton, C, Banham, A, Pulford, K

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. by Lawrie, C, Gal, S, Dunlop, H, Pushkaran, B, Liggins, A, Pulford, K, Banham, A, Pezzella, F, Boultwood, J, Wainscoat, J, Hatton, C, Harris, A

“…We therefore investigated whether microRNAs also have diagnostic utility by comparing levels of tumour-associated MIRN155 (miR-155), MIRN210 (miR-210) and MIRN21 (miR-21) in serum from diffuse large B-cell lymphoma (DLBCL) patients (n = 60) with healthy controls (n = 43). …”

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. by Ait-Tahar, K, Liggins, A, Collins, G, Campbell, A, Barnardo, M, Lawrie, C, Moir, D, Hatton, C, Banham, A, Pulford, K

“…The identification of immunogenic cancer testis antigens (CTAs) as immunotherapeutic targets represents one approach to improve treatment options for diffuse large B-cell lymphoma (DLBCL). We previously identified PASD1 [PAS (Per ARNT Sim) domain containing 1 (PASD1)], a DLBCL-associated CTA that was expressed in a range of hematopoietic malignancies. …”

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. by Ait-Tahar, K, Liggins, A, Collins, G, Campbell, A, Barnardo, M, Cabes, M, Lawrie, C, Moir, D, Hatton, C, Banham, A, Pulford, K

“…Since CD4-positive T helper cells have crucial roles in promoting and maintaining immune responses to tumor antigens, the presence of a CD4-positive T-helper immune response to the PASD1 antigen in patients with diffuse large B-cell lymphoma was investigated in the current study. DESIGN AND METHODS: Thirty-one patients with diffuse large B-cell lymphoma (25 with de novo, five with transformed and one with T-cell-rich B-cell lymphoma) were studied. …”

MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas. by Liggins, A, Cooper, C, Lawrie, C, Brown, P, Collins, G, Hatton, C, Pulford, K, Banham, A

“…The OX-TES-4 antigen originally elicited an antibody response in 50% of diffuse large B-cell lymphoma (DLBCL) patients but not in control subjects. …”

Erratum: Serologic detection of diffuse large B-cell lymphoma-associated antigens (International Journal of Cancer (2004) 110 (563-569)) by Liggins, A, Guinn, B, Hatton, C, Pulford, K, Banham, A

Sp17 protein expression and major histocompatibility class I and II epitope presentation in diffuse large B cell lymphoma patients by Ait-Tahar, K, Anderson, A, Barnardo, M, Collins, G, Hatton, C, Banham, A, Pulford, K

“…Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. …”

MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. by Lawrie, C, Soneji, S, Marafioti, T, Cooper, C, Palazzo, S, Paterson, J, Cattan, H, Enver, T, Mager, R, Boultwood, J, Wainscoat, J, Hatton, C

“…Diffuse large B cell lymphoma (DLBCL) is an aggressive malignancy that accounts for nearly 40% of all lymphoid tumors. …”